(NasdaqGM:IMDX),
NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q2 2025 Earnings Webinar.
An archived replay will be available after the call concludes on iMDX's investor relations website at https://investors.imdxinc.com/.
10th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
Separately, on August 12th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference, taking place from August 11-12, 2025.
Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Needham sales representative.
Event: 10th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
Dates: August 12, 2025
Location: Virtual
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.
iMDx(TM), GraftAssureCore(TM), GraftAssureIQ(TM), GraftAssureDx(TM), and VitaGraft(TM) are trademarks of Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company's new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
dfarrell@lifesciadvisors.com
